News &amp; Updates

Meaning-centred group psychotherapy for cancer survivors (MCGP-CS) has lasting benefits on participants’ sense of personal growth and on their positive relations with other people, reports a new study.

Meaning-centred group psychotherapy for cancer survivors effective in the long run

Healthy eating factors in long-term breast cancer survival

Breast cancer survivors may do well to adhere to healthy dietary patterns, which help cut the risk of mortality and breast cancer-specific recurrence or/and death, a study has found.

Healthy eating factors in long-term breast cancer survival

Activity restriction contributes to worse mental health in cancer survivors

Activity restriction appears to mediate the relationship between perceived pain and depression in cancer survivors, a new study has found.

Activity restriction contributes to worse mental health in cancer survivors

Insurance, pharmacy transfers delay receipt of novel oral oncolytics

Insurance can influence the time-to-receipt of newly prescribed novel oral oncolytics, while pharmacy transfers and cost assistance application also prolong wait times for patients, according to the results of a single-institution investigation.

Insurance, pharmacy transfers delay receipt of novel oral oncolytics

Ipilimumab therapy may improve survival in uveal, mucosal melanoma

Treatment with ipilimumab appears to increase survival in patients with uveal and mucosal melanoma, according to a multicentre, retrospective study.

Ipilimumab therapy may improve survival in uveal, mucosal melanoma

Electronic nose sniffs out Barrett’s oesophagus

06 Mar 2020 by

A high atherogenic index of plasma (AIP) is a strong risk factor for developing subclinical renal damage (SRD) and is associated with estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatine ratio (uACR), a recent study has shown.A novel electronic nose device can reliably detect Barrett’s oesophagus (BO) and may present an efficient, minimally invasive option for early detection of oesophageal adenocarcinoma (OAC), according to a recent study.

Electronic nose sniffs out Barrett’s oesophagus

Molecularly guided therapy extends OS by 1 year in pancreatic cancer in real-world settings

06 Mar 2020 by

Patients with pancreatic cancer with actionable mutations may have their overall survival (OS) extended by 1 year with molecularly matched therapies compared with unmatched therapies, a retrospective analysis of real-world data has shown.

Molecularly guided therapy extends OS by 1 year in pancreatic cancer in real-world settings

Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients

06 Mar 2020 by

A regimen consisting of obinutuzumab plus fludarabine and cyclophosphamide achieves favourable outcomes with manageable toxicity in the treatment of chronic lymphocytic leukaemia (CLL) in physically fit adults, poised as an attractive first-line option in patients who are eligible for potent chemoimmunotherapy, according to data from the phase IIIb GREEN trial.

Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients